CHEK1

Serine/threonine-protein kinase Chk1

205,325 patent compounds predicted against CHEK1, 121,808 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL150384	1.00	20/20
SCHEMBL147483	0.82	20/20
SCHEMBL146998	0.74	20/20
SCHEMBL145013	0.73	20/20
SCHEMBL145120	0.72	20/20
SCHEMBL21169	0.55	20/20
SCHEMBL20693	0.53	20/20
SCHEMBL19015	0.51	20/20
SCHEMBL144982	0.76	19/20
SCHEMBL144155	0.66	19/20
SCHEMBL31357	0.50	19/20
SCHEMBL31358	0.50	19/20
SCHEMBL141682	0.68	18/20
SCHEMBL144154	0.65	18/20
SCHEMBL144227	0.69	17/20
SCHEMBL144138	0.66	17/20
SCHEMBL146846	0.66	17/20
SCHEMBL142662	0.64	17/20
SCHEMBL143237	1.00	16/20
SCHEMBL146834	0.76	16/20

Germline variants in CHEK1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CHEK1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CHEK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer	PHASE1/PHASE2	COMPLETED
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis	PHASE2	ACTIVE_NOT_RECRUITING
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects	PHASE1/PHASE2	COMPLETED
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers	PHASE1/PHASE2	COMPLETED
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)	PHASE2	RECRUITING
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency	PHASE2	COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Niraparib and Dostarlimab in HRD Solid Tumors	PHASE2	UNKNOWN
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy	PHASE2	COMPLETED
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations	PHASE2	COMPLETED
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.	PHASE2	ACTIVE_NOT_RECRUITING
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	PHASE1	COMPLETED
A Clinical Study of TQB3824 in Subjects With Advanced Cancer	PHASE1	UNKNOWN
Tabectedin to Treat Children and Adolescents With Cancer	PHASE1	COMPLETED
A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer	PHASE1	COMPLETED
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors	PHASE1	RECRUITING
Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein	nan	COMPLETED
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer	nan	UNKNOWN
DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CHEK1 binder may also engage these)

Protein	Name	Similarity
O35280	—	1.000	O35280 →
Q91ZN7	—	1.000	Q91ZN7 →
Q8AYC9	—	0.996	Q8AYC9 →
Q6DE87	—	0.994	Q6DE87 →
Q28GW8	—	0.984	Q28GW8 →
MELK	Maternal embryonic leucine zipper kinase	0.981	landscape →
P62205	—	0.979	P62205 →
Q91821	—	0.979	Q91821 →
MAPK8	Mitogen-activated protein kinase 8	0.978	landscape →
F1QGZ6	—	0.978	F1QGZ6 →
P49187	—	0.976	P49187 →
Q61846	—	0.975	Q61846 →
Q90ZY4	—	0.974	Q90ZY4 →
Q2TA25	—	0.974	Q2TA25 →
Q2RAX3	—	0.973	Q2RAX3 →
O54785	—	0.973	O54785 →
Q9ESL4	—	0.973	Q9ESL4 →
P53666	—	0.973	P53666 →
P49186	—	0.972	P49186 →
Q9Z265	—	0.972	Q9Z265 →
MAP4K5	Mitogen-activated protein kinase kinase kinase kinase 5	0.971	landscape →
Q6NU47	—	0.971	Q6NU47 →
Q8QHK8	—	0.971	Q8QHK8 →
Q62673	—	0.971	Q62673 →
MAPK10	Mitogen-activated protein kinase 10	0.971	landscape →
A7MBL8	—	0.971	A7MBL8 →
O54863	—	0.970	O54863 →
LIMK2	LIM domain kinase 2	0.970	landscape →
P49185	—	0.970	P49185 →
O54992	—	0.970	O54992 →